Anti-Human CD28 (Clone 9.3) – Biotin

Human T lymphocytes

This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2 – 8° C Wet Ice

The Anti-Human CD28 Mouse IgG2a, Clone 9.3 antibody, targets human CD28

CD28, a glycoprotein weighing 44 kDa is a member of the Ig superfamily and plays a vital role, in the activation and survival of T cells^{1, 2} by enhancing the production of interleukin and the activity of T cells. CD28 is unique among B7 receptors as it is consistently expressed on T cells. The interaction between CD28 and B7 is crucial for preventing T cells from becoming anergic and unable to respond to antigen/MHC complexes highlighting its role in an immune response^3-6.

The clone 9.3 has gained recognition for its ability to stimulate the growth of human T cells in vitro making it a valuable tool for research focused on studying T cell activation and immune responses. It was developed by immunizing mice with human T cells. It has demonstrated effectiveness in inducing T cell activation and proliferation when combined with TPA thereby influencing IL 2 receptor expression and IL 2 production⁷. This clone can be utilized for staining a portion of T cells through immunofluorescence methods and has proven successful in immunoprecipitating CD28 from Jurkat cells⁸. Given its ability to activate T cells and its reactivity with CD28, the 9.3 clone stands as a resource for research.

CD28 is primarily expressed by thymocytes, most peripheral T cells, and natural killer (NK) cells.

CD80 (B7-1) and CD86 (B7-2)

1. Porciello N, Tuosto L. Cytokine Growth Factor Rev. 2016;28:11-19.
2. Xia S, Chen Q, Niu B. Curr Drug Targets. 2020;21(6):589-598.
3. Eck SC, Chang D, Wells AD, Turka LA. Transplantation. 1997;64(10):1497-1499.
4. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. J Exp Med. 1991;173(3):721-730.
5. Wu Y, Guo Y, Huang A, Zheng P, Liu Y. J Exp Med. 1997;185(7):1327-1335.
6. Sperling AI, Auger JA, Ehst BD, Rulifson IC, Thompson CB, Bluestone JA. J Immunol.1996;157(9):3909-3917.
7. Baroja ML, Lorre K, Van Vaeck F, Ceuppens JL. Cell Immunol. 1989;120(1):205-217.
8. Hara T, Fu SM, Hansen JA. Human T cell activation. II. J Exp Med. 1985;161(6):1513-1524.
9. Kovacs B, Parry RV, Ma Z, et al. J Immunol. 2005;175(12):7848-7854.
10. Bushkin Y, Radford F, Pine R, et al. J Immunol. 2015;194(2):836-841.
11. Hill EV, Ng THS, Burton BR, Oakley CM, Malik K, Wraith DC. Eur J Immunol. 2015;45(4):1103-1115.
12. Huang X, Williams JZ, Chang R, et al. Nat Nanotechnol. 2021;16(2):214-223.
13. Siefken R, Klein-Hessling S, Serfling E, Kurrle R, Schwinzer R. J Immunol. 1998;161(4):1645-1651.